Abstract PD7-11: Impact of neoadjuvant pembrolizumab on ovarian function in young patients with triple-negative breast cancer (TNBC): Longitudinal analysis from NeoSTOP and NeoPACT trials

Clinical Cancer Research 2026

View at publisher
Authors: P. Sharma, Rachel Yoder, W. Cui, Amy Winship, Karla J. Hutt, Sandra Loi, Q. J. Khan, A. O'Dea, Lauren Elizabeth Nye, Deepti Satelli, Joshua M. Staley, Rajni V. Puri
+7 more Amrita Mitra, K.-A. Phillips, Lauren R. Alesi, Yasmin Lewis, Joyce O’Shaughnessy, Harsh B. Pathak, A. K. Godwin
DOI: 10.1158/1557-3265.sabcs25-pd7-11
Cited by: 0

Abstract

Abstract Background: Neoadjuvant chemotherapy plus pembrolizumab (NACT+P) is standard of care for most patients with stage II-III TNBC. There is lack of clinical data on the ovarian toxicity of immune checkpoint inhibitors in patients with breast cancer. We utilized serial serum samples and data from two completed neoadjuvant trials, NeoSTOP (NACT: carboplatin + paclitaxel-->AC or carboplatin + docetaxel) and NeoPACT (NACT+P: carboplatin + docetaxel + pembrolizumab) to compare ovarian toxicity of chemotherapy and chemoimmunotherapy. Methods: Patients

Fields of Study & Subjects

Reproductive Biology and Fertility Breast Cancer Treatment Studies BRCA gene mutations in cancer

Publication details

Journal / source
Clinical Cancer Research
Volume
32
Issue
4_Supplement
Pages
PD7–11
Publication date
17 February 2026
Language
EN